FDA Approves Ozempic® as First GLP-1 RA to Reduce Kidney Disease Progression & Mortality in Type 2 Diabetes
Time to read: 00:56 The U.S. Food and Drug Administration (FDA) has approved Ozempic® (semaglutide) to reduce the risk of kidney disease progression, kidney failure, and cardiovascular-related death in adults with type 2 diabetes and chronic kidney disease (CKD).
Source: PR Press Wire
Feature
Text
Novartis presents results of pre-specified interim analysis of the Phase III APPLAUSE-IgAN study of Fabhalta® (iptacopan), for treatment of patients with IgA nephropathy (IgAN)1
Novartis has unveiled interim results from the Phase III APPLAUSE-IgAN study of Fabhalta® (iptacopan), an investigational Factor B inhibitor of the alternative complement pathway, in patients with IgA nephropathy (IgAN)1.
Source: PR Newswire
Text
